Munich, Germany, June 25, 2024 – Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, announced today preliminary positive data from its Phase 1 dose escalation clinical trial evaluating the safety, tolerability, and target engagement of lead mRNA candidate ETH47 encoding interferon lambda (IFNλ), in healthy participants. IFNλ has a key role in viral immunity in the respiratory tract. The data indicates that ETH47, administered nasally, was generally safe and well-tolerated, with no severe adverse events or drug-related adverse events of clinical relevance across all dose levels. Initial results also show target engagement and suggest no systemic biodistribution of ETH47. A full data readout is planned for the third quarter of 2024. 

Munich, Germany, June 18, 2024 – Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, announced today that it has received funding from the Gates Foundation to support the advancement of the company’s lead mRNA-based product candidate, ETH47. This funding of $5 million includes an equity investment component expected to close at the company’s next financing round. The new capital will enable the company to rapidly reach Phase 2 readiness and build out the CMC manufacturing process for the next clinical trial. 

Mumbai, India and Munich, Germany: June 18, 2024: Cipla Limited today announced that its wholly-owned subsidiary in United Kingdom, Cipla (EU) Limited (hereinafter together referred as “Cipla”) will invest an additional EUR 3 million in Ethris GmbH (“Ethris”), a global leader in delivering mRNAs directly to the respiratory system. This additional investment through a convertible loan will accelerate Cipla’s participation in the mRNA space. 

Munich, Germany, December 18, 2023 – Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced the dosing of the first healthy participant in its first-in-human study of lead candidate ETH47, which was developed using Ethris’ Stabilized Non-Immunogenic mRNA (SNIM®RNA) platform and encodes for type III interferon (IFN) that plays a vital role in early antiviral response. ETH47 was also designed to be administered locally to the lung through inhalation or nasal spray using the company’s proprietary Stabilized NanoParticle (SNaP) LNP platform. The Phase 1 study will primarily evaluate ETH47’s safety and tolerability in healthy participants. The program, although initially focused on virus-induced asthma, has the potential to be applied for pandemic preparedness against influenza and SARS-CoV-2 due to its broad applicability. 

Munich, Germany, November 28, 2023 – Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced that it has received approval from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with a Phase 1 clinical trial for its inhaled mRNA program, ETH47, in healthy participants for the treatment and prophylaxis of respiratory viral infections. The authorization follows Ethris’ submission of a Clinical Trial Authorization (CTA) application to the MHRA in June 2023. The Phase 1 study is expected to commence in the U.K already in December 2023.

Munich, Germany, and London, United Kingdom, November 13, 2023 – Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Heqet Therapeutics, a biotechnology spin-out company from King’s College London active in the field of regenerative medicine, today announced a collaboration agreement to harness the potential of ncRNA for heart tissue regeneration following acute myocardial infarction (heart attack) and in heart failure. Under the terms of the agreement, Heqet Therapeutics will lead the development of the program, while Ethris will provide its proprietary Stabilized NanoParticle (SNaP) LNP platform to deliver ncRNA payloads to the heart tissue. 

Munich, Germany, November 1, 2023 - Ethris GmbH, a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, announced today it will be a founding member of a new global organization called Alliance for mRNA Medicines (AMM). 

Munich, Germany and Cambridge, United Kingdom, September 25, 2023

Ethris and DIOSynVax, a Cambridge UK based clinical stage biotech spinout specialized in the development of multi-valent vaccine antigen payloads (VAPs), announced today the publication of preclinical proof of concept results for each of their platform technologies in Nature Biomedical Engineering.

Munich, Germany, December 21, 2022

Ethris announced today a collaboration with UK-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of Betacoronaviruses utilizing the company’s highly differentiated mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilisation platforms.

Mumbai, India and Munich, Germany: December 29, 2022

Ethris announced today that it has signed a definitive agreement with Cipla for an equity investment of EUR 15 million in Ethris.

Munich, Germany, February 1, 2022

Ethris GmbH, a leading biotechnology company pioneering transformative messenger RNA (mRNA) therapeutics, announced today that it has raised $26.3 Million (€23.3 Million) in a Series B financing round led by Laureus Capital.

Munich, Germany, September 15, 2021

Ethris GmbH announced today that its lead COVID-19 therapeutic candidate, ETH47, has been awarded “The Most Innovative Product Top 3” in the category of Leap Innovations at the Pharma Trend Image & Innovation Awards 2021.

Munich, Germany, March 30, 2021

Funding will advance Ethris’ development of an mRNA-based therapeutic to treat SARS-CoV-2 and its variants

Zurich, Switzerland and Munich, Germany, April 1, 2020

Neurimmune AG and Ethris GmbH announced today an exclusive partnership to develop mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies administered by inhalation for the treatment of Covid-19.

Munich, Germany, June 3, 2019

Ethris announced  the expansion of the company’s leadership team by the addition of Thomas Langenickel, M.D. in the role of Chief Medical Officer. Dr. Langenickel joined Ethris from Novartis AG, where he was Executive Director and Head of Respiratory Profiling within the Translational Medicine Group.

Munich, Germany, October 1, 2019

Ethris’ existing collaboration with the Munster University Hospital has been awarded a research grant by the Central Innovation Program for SMEs (ZIM). The funding will help accelerate the joint research project in primary ciliary dyskinesia (PCD), including evaluation of ETH42, a first-in-class SNIM®RNA product in preclinical development.

Munich, Germany, December 07, 2018

Ethris adapted the responsibilities among its leadership team to position the company for the next phase of its development. As a result, Dr. Gita Dittmar took on the role as Chief Executive Officer, PD Dr. Carsten Rudolph became Chief Scientific Officer and Prof. Dr. Christian Plank became Chief Technology Officer.

Munich, Germany, August 21, 2017

Ethris  and AstraZeneca signed a five-year strategic research collaboration that is focused on developing new stabilized non-immunogenic modified RNA therapies for respiratory diseases using Ethris’ proprietary SNIM®RNA technology. Ethris received €25 million upfront plus research funding and is eligible for future research and development milestones, including sales related royalties upon commercialization.

Munich, Germany, July 19, 2016

Ethris announced the addition of Dr. Leon Chen, Dr. Thomas Chalberg, and Justin Duckworth to the Ethris Board of Directors to support the next stage of the company’s development.

Munich, Germany, March 21, 2016

Ethris announced the publication of a research paper in the peer-reviewed journal “Biomaterials” that underlines the broad therapeutic potential of the company’s proprietary mRNA transcript therapy platform. The paper demonstrates that a modified mRNA construct based on Ethris’ technology coding for the human growth factor BMP-2 (bone morphogenetic protein-2) can induce bone regeneration in three different settings including an established in-vivo model for bone healing.